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During the past decade there has been a substantial increase in macroautophagy 
(herein simply referred to as autophagy) research due to a growing understan-
ding of this process, coupled with improved new techniques for its detection. 
Autophagy (auto — self, phagy — eating) is defined as a fundamental lysosomal 
catabolic pathway responsible for degrading long-lived proteins, protein aggre-
gates, oxidised lipids, damaged organelles, and even microbial invaders. Although 
autophagy occurs at basal levels in normal conditions, many different forms of 
metabolic stress, including starvation, hypoxia, high temperature, high culture 
density, hormones, and growth factor deprivation can dramatically stimulate 
an autophagic response. Autophagy plays a critical role in maintaining cellular 
homeostasis and genomic integrity and therefore has been implicated in many 
physiological activities such development, differentiation, and tissue remodelling. 
Consequently, defects in autophagy have been linked to various human diseases 
such as neurodegenerative and muscle disorders, cancers, cardiac failure, and 
inflammatory disorders. This mini-review summarises current knowledge in a field 
of mammalian autophagy and considers the significance of autophagy in human 
physiology and pathology. (Folia Morphol 2013; 72, 2: 87–93)
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INTRODUCTION
The autophagic process was first described by Clark 
in 1957 using electron microscopy, but the term “au-
tophagy” was introduced for the first time in 1963 by 
Christian de Duve, who was awarded the Nobel Prize for 
his work on lysosomes. Autophagy (auto — self, phagy 
—  eating) is defined as an evolutionarily conserved 
and strictly regulated lysosomal pathway that degrades 
cytoplasmic material and organelles and even microbial 
invaders [22, 36, 37, 39]. The other major degrading sy-
stem, which is present only in mammals, is the ubiquitin-
-proteasome system (UPS) [44]. The UPS degrades soluble 
short-lived proteins, which must be tagged by ubiquitin 
to be recognised by the proteasome. The process of 
autophagy has different mechanisms and routes for the 
elimination of cytoplasmic components, and therefore 
it can be more precisely subdivided in 3 types: macro-
autophagy, microautophagy, and chaperone-mediated 
autophagy [54]. Micro- and macroautophagy are both 
highly evolutionary conserved from yeast to humans, 
while chaperone-mediated autophagy is a selective form 
of autophagy that has only been observed in mamma-
lian cells [37, 50]. Macroautophagy represents the most 
extensively studied form of autophagy and involves the 
prominent formation of double-membrane vesicles ter-
med autophagosomes, which surround and randomly 
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sequester cytoplasmic constituents prior to fusion with 
lysosomes [7, 22, 37, 48, 54]. In general, autophagy is 
considered to be a non-selective pro-survival cellular re-
sponse; however, several forms of autophagy that display 
selectivity, e.g. mitophagy (degrades mitochondria), reti-
culophagy (degrades endoplasmic reticulum), xenophagy 
(degrades microorganisms), and aggrephagy (degrades 
aggregated proteins), have been recognised [18, 21]. 
Autophagy is extensively studied due to the identification 
of many autophagy-related genes (ATG) coupled with 
improved methods for monitoring this process [23, 30, 
43]. Although substantial progress has been achieved in 
elucidating the autophagic machinery, the mechanism 
of formation of autophagosome is still unclear. Several 
different assays are available to monitor autophagy, but 
using a combination of them is recommended. The most 
traditional method used to detect autophagosomes is 
electron microscopy; therefore, conventional morpho-
metry is currently the standard for assessing autophagy, 
both in tissues and in cultured cells. Nevertheless, the 
electron microscopy method is limited in its potential, 
and thus new methods for identifying and quantifying 
and also for modulating autophagic activity was applied 
[19, 23, 38, 55]. Fluorescence microscopy is a powerful 
method for the detection of molecules involved in the 
autophagosome biogenesis. To date, LC3 — a micro-
tubule-associated protein 1 light chain 3 — is the only 
well-characterised protein that is specifically localised to 
autophagic structures throughout the process from pha-
gophore to lysosomal degradation [55]. The number of 
autophagosomes usually correlates well with the amount 
of LC3-II punctate structures, and therefore it can usually 
be visualised using fluorescence microscopy and analy-
sed with image analysis software. The LC3-II expression 
can be also quantitatively and sensitively monitored by 
immunoblot analysis or flow cytometry. Although LC3-II 
is a promising autophagosomal marker, it is necessary to 
carefully interpret the results because increased LC3-II 
levels can be associated with either enhanced autopha-
gosome synthesis or reduced autophagosome turnover. 
Because autophagy is a dynamic and continuous process, 
the autophagy flux is necessary to differentiate whether 
the accumulated autophagosomes are due to increased 
production or reduced degradation. One of the principal 
methods to measure autophagic flux is the monitoring 
of LC3-II turnover, which is based on the observation of 
differences in LC3-II levels in the presence and absence 
of lysosome inhibitors, such as chloroquine [19, 55]. 
The aUTOphagOsOmal paThway 
Autophagy delivers cytoplasmic constituents to lyso-
somal degradation via the formation of an autophagoso-
me [7, 8, 20, 30, 43]. Morphological trials of autophagy 
consist of several sequential stages (Fig. 1): initiation, 
nucleation, elongation, closure, maturation, and finally 
degradation and export of materials to the cytoplasm. 
Initiation
In the initial step, a cup-shaped double membrane 
structure, known as the “isolation membrane”, is 
formed (Fig. 1). This unique perivacuolar structure, 
termed the phagophore, has been proposed as the 
Figure 1. Schematic diagram of autophagic progression in mammalian cells. Following induction of autophagy, cytoplasmic components 
become sequestered by a flat membrane sheet known as the isolation membrane or phagophore. Finally, the expanding membrane sac fully 
encloses the object destined for elimination to form a double-membrane vesicle, the autophagosome. Fusion between the autophagosome 
and lysosome, often referred to as autophagic flux or maturation, generates an autolysosome (autophagolysosome). Intra-autophagosomal 
contents as well as the inner autophagosomal membrane are degraded by the lysosomal hydrolases. In the final step of autophagy, macro- 
molecules generated from degraded cargo are transported back to the cytosol for reuse.
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precursor of autophagosome — a double-membrane 
vesicle containing cytoplasmic constituents [2, 31, 37, 
43, 48, 57]. The exact origin of the isolation memb-
rane is still controversial, but probably there is not 
a single source. It seems likely that the ribosome-free 
region of the rough endoplasmic reticulum, mito-
chondrial outer membrane, or Golgi compartments 
are the sources for the phagophore [13, 22]. 
Elongation and closure 
Phagophore elongates and completely captures the 
sequestered cargo to form the double-membrane au-
tophagosome, or “autophagic vacuole”. Sequestration 
can be either nonspecific, involving the engulfment of 
bulk cytoplasm, or selective, targeting specific cargoes 
such as organelles or invasive microbes [2, 7, 22]. Au-
tophagosomes form randomly in the cytoplasm and 
the size of typical autophagosomal double-membrane 
vacuoles ranges from 300 to 900 nm. This step is 
a simple sequestration, and no degradation occurs.
Maturation and degradation 
After formation, the completed autophagosome 
undergoes a stepwise maturation process including its 
conversion into a degradative organelle, termed autolyso-
some, by fusion with late endosomal and lysosomal orga-
nelles. Some recent studies have revealed the importance 
of cytoskeletal elements, such as actin microfilaments 
and microtubules, in specific aspects of autophagy [7, 
24]. Autophagosomes are trafficked along microtubu-
les in a dynein-dependent manner to lysosomes, which 
are clustered around the microtubule-organising centre 
(MTOC; located near the nucleus). There, autophagosome 
docks with the lysosome, and the outer membrane of the 
autophagosome successively fuses with the membrane 
of the lysosome. The inner membrane is finally consu-
med together with the cargo by resident hydrolases. 
In addition, the autophagosomes can first fuse with 
other vesicles including endosomes and multivesicular 
bodies to form hybrid organelles called amphisomes 
that later fuse with lysosomes, where the entrapped 
cytosolic contents are degraded [57]. It is currently not 
clear whether amphisome formation is a prerequisite for 
autophagosome-lysosome fusion. An autophagosome 
that has fused with a lysosome subsequently matures to 
become single-membrane degradative organelle autoly-
sosome often called “autophagolysosome” [36, 40, 41, 
54]. Acidification and acquisition of hydrolytic enzymes, 
including proteases, lipases, nucleases, and glycosidases, 
enable the autolysosome to degrade sequestered intra-
-autophagosomal components [30, 36]. The breakdown 
products are then transferred back into the cytoplasm 
where they can either be recycled or further catabolised. 
Whereas the mobility of autophagic vacuoles is depen-
dent on microtubules, fusion seems to be independent 
of cytoskeletal elements [24]. The definition of the va-
cuoles named above is based on their function, not on 
their morphology. Therefore, it is not easy to distinguish 
autophagosomes, amphisomes, and autolysosomes by 
electron microscopy. Although some methods to monitor 
autophagy flux have been presented, the degradation 
step is rather difficult to measure [38]. In particular, distin-
ction of autolysosomes from other cellular membranous 
compartments is often more difficult. The maturation of 
autophagosomes is a relatively quick process, and under 
starvation conditions all of the described events occur 
within 10–15 min [23, 54].
RegUlaTION Of aUTOphagIC aCTIvITy
In mammals, the formation of autophagosomes 
appears to be a highly coordinated, multistep process 
controlled by a specific set of genes described by a com-
mon name, ATG. Genetic screening in yeast originally 
identified more than 30 different ATG genes, and many 
of these have mammalian homologs [22, 39, 48, 50]. 
In the early stages of autophagosome formation, the 
nucleation of autophagic vacuoles requires the activity 
of the class-III phosphoinositide 3-kinase (PI3K), which 
is part of a large macromolecular specific complex that 
contains the important protein Atg6 (also called beclin 
1) [3]. In mammals, at least 3 types of III PI3-kinase com-
plexes contribute to autophagy, and thus autophago-
some formation is positively regulated by Rab7 and the 
UV-RAG-Vps34-beclin1 PI3-kinase complex, whereas it 
is negatively regulated by the Rubicon-UV-RAG-Vsp34-
-beclin1 complex [50, 61]. While PI3 generated by Beclin-1 
containing complexes marks sites of autophagosome 
generation, 2 ubiquitin-like systems are required for 
elongation of phagophore and the maturation of au-
tophagosomes [40, 54]. Atg5 and Atg12 are involved 
in the first of 2 ubiquitylation-like reactions that interact 
non-covalently with Atg16L (Atg16-like) to form a com-
plex. The second ubiquitylation-like reaction involves 
the cleavage of microtubule-associated protein 1 light 
chain 3 (MAP1-LC3) also known as Atg8 or LC3 in mam-
mals, and its subsequent conjugation to a phospholipid, 
phosphatidylethanolamine (PE), to form LC3-II in the 
autophagosomal membrane [3, 8]. LC3-II is a unique 
protein that specifically associates with newly forming 
autophagosome membranes and not with other vesicular 
structures [36]. LC3-II is present on both the cytosolic and 
the intra-autophagosomal surfaces and therefore increa-
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ses during autophagosome formation [40]. In mammals, 
the conversion of LC3 from LC3-I (free form) to LC3-II 
(PE-conjugated form) is regarded as a critical step in 
autophagosome formation [19]. Although Atg5-Atg12 
is lost upon completion of autophagosome formation, 
LC3-II remains associated with autophagosomes even 
after fusion with lysosomes, after which LC3-II on the 
cytosolic face of autolysosomes can be delipidated and 
recycled (to LC3-I). Thus the level of LC3-II correlates with 
the autophagosome number, and this specific association 
makes it an excellent marker for monitoring autophagy 
[40]. Crosstalk between the 2 mentioned ubiquitylation-
-like systems has also been suggested. Moreover, autop-
hagosome formation is tightly regulated by intracellular 
and extracellular amino acid concentrations and ATP le-
vels via major inhibitory signalling pathways that include 
the mammalian target of rapamycin, mTOR kinase [59]. 
This evolutionarily conserved TOR kinase complex 1 is 
a sensor of nutrient status and plays an important role 
in the control of cell growth. More detailed information 
on molecular machinery that regulates and executes 
autophagy can be found in several recent reviews on 
these topics [22, 39, 51, 54].
physIOlOgICal fUNCTIONs  
Of aUTOphagy
Autophagy occurs constitutively at low basal levels in 
all eukaryotic cells where it operates as a cellular quality 
control mechanism responsible for the normal turnover 
of intracellular components and maintenance of the 
cellular energetic balance [4, 25, 37, 52]. Under most cir-
cumstances, autophagy constitutes a stress adaptation 
pathway that promotes cell survival, and thus has been 
implicated in many fundamental physiological activities 
such as development, differentiation, and tissue remo-
delling [2, 39]. The breakdown products — amino acids, 
fatty acids, nucleosides, and carbohydrates — genera-
ted by autophagy, released by lysosomal permeases, can 
be delivered systemically and exported to the cytosol 
for reuse (Fig. 2). Moreover, the amino acids liberated 
from autophagic degradation can be, together with 
the fatty acids, used by the tricarboxylic acid cycle to 
maintain cellular ATP production [3]. Autophagy can be 
rapidly upregulated by numerous stressors including, 
among others, nutrient starvation, hormone and gro-
wth factor deprivation, high temperature or hypoxia, 
or pharmacological agents (e.g. rapamycin) [8, 27, 36]. 
The best-known evolutionary conserved stress response 
in eukaryotes is stimulation of autophagy during a pe-
riod of starvation, both in cultured cells and in intact 
organisms [28, 40, 50]. Recently, it was appreciated that 
macroautophagy not only contributes to the turnover 
of cytoplasmic constituents, but also targets intracellu-
lar pathogens for degradation during innate immunity 
[5]. This housekeeping function of autophagy includes 
the direct elimination of certain intracellular microbial 
pathogens via a process termed xenophagy. Elimina-
ting many bacteria (group A Streptococcus, Staphylo-
coccus aureus, Mycobacterium tuberculosis, Ricketssia 
coronii), parasites (Toxoplasma gondii), and viruses 
(herpes simplex virus type I), autophagy participates 
in the cell-autonomous antimicrobial defence system 
Figure 2. The role of autophagy in human physiology and disease (see text for details).
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[5, 31]. Moreover, autophagy plays critical functions in 
regulating adaptive immune responses, immunological 
tolerance, and the development and homeostasis of 
the immune system [16, 32, 45]. In nervous system, 
the stimulation of autophagy limits the accumulation 
of toxic products and protects neurons against degene-
ration [15, 50, 53, 57]. In muscle the heart cells basal 
autophagy seems to have a special housekeeping role 
in the turnover of cytoplasmic constituents, including 
mitochondria, and is upregulated in response to stress 
[17]. The findings of LaRocca et al. [29] also suggest 
that autophagy preserves arterial endothelial function 
by reducing oxidative stress and inflammation and 
increasing nitric oxide bioavailability. It has also been 
suggested that autophagy participates in the degra-
dation of mitochondria during reticulocyte maturation 
[12]. Lipid droplets from the liver are eliminated by 
their constitutive degradation in autolysosomes [48], 
but on the other hand, autophagy is required for the 
production of the large lipid droplets characteristic of 
the white adipose tissue. The anti-aging role of auto- 
phagy probably depends on its quality control function 
that limits the production of reactive oxygen species 
by the deposition of aggregation-prone proteins and 
damaged mitochondria [1, 4]. Recent genetic analyses 
in various organisms have resulted in the identification 
of genes involved in controlling longevity [6, 10]. Gro-
wing evidence has indicated both classical autophagy 
(macroautophagy) and chaperone-mediated auto- 
phagy decline with aging in rodents and probably in 
humans [49]. A cardinal feature of aging postmitotic 
cells is the accumulation of yellowish-brown, autoflu-
orescent lipofuscin deposits [1].
A critical physiological role of autophagy appears 
to be cytoprotection, but this process is also associa-
ted with cell death through its intertwined relation-
ships with apoptosis and necrosis [10, 11, 30, 42]. 
Some studies implicate that excessive degradation 
of cellular constituents contributes to a form of cell 
death, usually referred to as Type II programmed cell 
death or autophagic cell death (ACD), characterised 
by a large-scale sequestration of portions of the cyto-
plasm, giving the cell a characteristic vacuolated ap-
pearance. ACD also occurs in a caspase-independent 
manner, without key features of apoptotic morpho-
logy, such as chromatin condensation and nuclear 
fragmentation [27]. Nevertheless, autophagy and 
apoptosis share several common regulatory elements, 
which suggests a dual role of autophagy in cell sur-
vival and cell death [6, 11].
aUTOphagy: RelaTeD paThOlOgIes 
Alterations in autophagy have been linked to 
a wide range of pathological conditions including 
neurodegeneration, myopathy, liver disease, diabetes, 
and cancer [16, 30, 31, 36, 46, 51, 53, 58]. Especially 
in nonproliferative cells, such as neurones and myocy-
tes where normal turnover of cytoplasmic contents 
may be critical, impairment of autophagy contribute 
to neurodegeneration or muscle atrophy [42, 56, 
59]. Examples demonstrate extended accumulation 
of polyglutamine-containing proteins that cause 
Huntington’s disease, mutant forms of a-synuclein 
that cause Parkinson’s disease, and amyloid plaqu-
es consisting of b-amyloid (Ab) peptides that cause 
Alzheimer’s disease [47, 53, 56, 59]. However, it is 
important to underline that the role of autophagy in 
protection against neurodegenerative diseases has 
been established in animal models but not yet in pa-
tients [15, 25, 40]. The other diseases associated with 
blockade of the autophagic pathway are muscular di-
sorders, known as vacuolar myopathies [46]. Massive 
accumulation of imperfect autophagic or lysosomal 
vacuoles can be observed in patients suffering from 
Danon’s disease, which has clinical characteristics 
including cardiomyopathy, myopathy, and variable 
mental retardation [50]. 
The contribution of autophagy to cancer deve-
lopment, especially in resistance to some anticancer 
treatments, is widely accepted. Although it is gene-
rally agreed that autophagy is low in cancer cells, 
increasing evidence supports both tumour promoting 
and suppressive functions of autophagy [11, 14]. It 
is hypothesised that autophagy maintains genomic 
integrity and thus would seem to be beneficial for 
cancer prevention during tumour initiation in certain 
circumstances [33, 35]. The loss of the essential au-
tophagy gene Beclin 1 (Atg6) has been observed in 
40% to 75% of human breast, prostate, and ovarian 
cancers [58], suggesting that autophagy may play 
a role in preventing these tumours. Several preclinical 
and clinical studies indicate that pharmacological 
inhibition of mTOR, which leads to the induction of 
autophagy, provides a powerful therapeutic tool for 
the treatment of various malignancies [51, 60]. In 
more advanced tumours during cancer progression, 
autophagy may, on the other hand, provide tumour 
cells with a survival strategy, thus suggesting a thera-
peutic use for autophagy down-regulation [reviewed 
in 31, 36]. Additionally, understanding the relation-
ship between autophagic and apoptotic pathways 
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may provide novel therapeutic approaches to treating 
drug-resistant cancers. 
The role of autophagy in immune response is not 
limited to the direct elimination of invading patho-
gens but also contributes to chronic inflammatory 
diseases and autoimmune diseases [16, 32, 45]. Per-
turbations in macroautophagy regulators have been 
reported in the Crohn’s disease, an inflammatory bo-
wel disorder affecting the small intestine [32]. Other 
potential links include systemic lupus erythematosus, 
inflammation-associated metabolic diseases such as 
obesity and diabetes, and inflammation associated 
with cystic fibrosis lung disease [34, 50]. Recent stu-
dies suggest that autophagy is necessary to maintain 
the structure, mass, and function of pancreatic b-cells 
under conditions such as oxidative stress, and that 
reduction in autophagic activity may contribute to 
a reduced ability to produce insulin [9]. It is hypothe-
sised that the disturbance of autophagy function in 
the liver could lead to progressive accumulation of 
aggregation-prone a1-antitrypsin. Such perturbations 
in autophagy have been associated with chronic liver 
disease and hepatocellular carcinoma [26]. Undoub-
tedly, a better understanding of the complexity of 
autophagy and its regulation may allow the practical 
use of autophagy for therapeutic purposes. 
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